These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27374748)

  • 1. HCV1b genome evolution under selective pressure of the cyclophilin inhibitor alisporivir during the DEB-025-HCV-203 phase II clinical trial.
    Cuypers L; Snoeck J; Kerremans L; Libin P; Crabbé R; Van Dooren S; Vuagniaux G; Vandamme AM
    Infect Genet Evol; 2016 Oct; 44():169-181. PubMed ID: 27374748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
    Le Pogam S; Seshaadri A; Ewing A; Kang H; Kosaka A; Yan JM; Berrey M; Symonds B; De La Rosa A; Cammack N; Nájera I
    J Infect Dis; 2010 Nov; 202(10):1510-9. PubMed ID: 20942646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance.
    Cuypers L; Li G; Libin P; Piampongsant S; Vandamme AM; Theys K
    Viruses; 2015 Sep; 7(9):5018-39. PubMed ID: 26389941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir.
    Garcia-Rivera JA; Bobardt M; Chatterji U; Hopkins S; Gregory MA; Wilkinson B; Lin K; Gallay PA
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5113-21. PubMed ID: 22802259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1.
    Jacobson I; Zeuzem S; Flisiak R; Knysz B; Lueth S; Zarebska-Michaluk D; Janczewska E; Ferenci P; Diago M; Zignego AL; Safadi R; Baruch Y; Abdurakhmanov D; Shafran S; Thabut D; Bruck R; Gadano A; Thompson AJ; Kopit J; McPhee F; Michener T; Hughes EA; Yin PD; Noviello S
    World J Gastroenterol; 2016 Mar; 22(12):3418-31. PubMed ID: 27022224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations.
    Pawlotsky JM; Germanidis G; Neumann AU; Pellerin M; Frainais PO; Dhumeaux D
    J Virol; 1998 Apr; 72(4):2795-805. PubMed ID: 9525599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
    Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
    Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of alisporivir for the treatment of hepatitis C infection.
    Stanciu C; Trifan A; Muzica C; Sfarti C
    Expert Opin Pharmacother; 2019 Mar; 20(4):379-384. PubMed ID: 30576256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of baseline polymorphisms for potential resistance to NS5A inhibitors in drug-naive individuals infected with hepatitis C genotypes 1-4.
    McCormick AL; Wang L; Garcia-Diaz A; Macartney MJ; Webster DP; Haque T
    Antivir Ther; 2015; 20(1):81-5. PubMed ID: 24621453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
    Berger KL; Scherer J; Ranga M; Sha N; Stern JO; Quinson AM; Kukolj G
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6017-25. PubMed ID: 26195509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
    Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in the NS5A gene are associated with response to interferon+ribavirin combination therapy in patients with chronic hepatitis C virus 3a infection.
    Ullah S; Rehman HU; Idrees M
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1146-51. PubMed ID: 23611896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
    Zeuzem S; Flisiak R; Vierling JM; Mazur W; Mazzella G; Thongsawat S; Abdurakhmanov D; Van Kính N; Calistru P; Heo J; Stanciu C; Gould M; Makara M; Hsu SJ; Buggisch P; Samuel D; Mutimer D; Nault B; Merz M; Bao W; Griffel LH; Brass C; Naoumov NV;
    Aliment Pharmacol Ther; 2015 Oct; 42(7):829-44. PubMed ID: 26238707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.
    Flisiak R; Feinman SV; Jablkowski M; Horban A; Kryczka W; Pawlowska M; Heathcote JE; Mazzella G; Vandelli C; Nicolas-Métral V; Grosgurin P; Liz JS; Scalfaro P; Porchet H; Crabbé R
    Hepatology; 2009 May; 49(5):1460-8. PubMed ID: 19353740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
    De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
    J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
    McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
    Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
    Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
    World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of viral escape mutations within HCV p7 during treatment with amantadine in patients with chronic hepatitis C.
    Vermehren A; Welsch C; Elsler U; Vermehren J; Herrmann E; Sarrazin C; von Wagner M; Susser S; Hofmann WP; Kronenberger B; Zeuzem S; Mihm U
    Antivir Ther; 2013; 18(6):803-11. PubMed ID: 23824381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.